Sleep drug YZJ-1139 put to the test in kidney patients
NCT ID NCT06671444
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study examines how the sleep aid YZJ-1139 behaves in people with severe kidney impairment compared to those with normal kidney function. Sixteen adults will receive a single 20 mg dose, and researchers will measure drug levels in the blood and urine, as well as any side effects. The goal is to understand if kidney problems change how the drug is processed, which could lead to safer dosing recommendations.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
YZJ-1139
What this could lead to
If successful, this study could provide dosing guidance for using YZJ-1139 in people with kidney disease, making the drug safer for this group.
What could go wrong
This is a very early, small study (16 people) focused on drug levels, not on treating insomnia. Results may not apply to all kidney patients or predict real-world effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INSOMNIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Bengbu Medical University
Bengbu, China
-
The First Affiliated Hospital of Xuzhou Medical University
Xuzhou, China
-
Zhongda Hospital Southeast University
Nanjing, Jiangsu, China